Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
A hypercoagulable state may either underlie or frankly accompany cancer disease at its onset or emerge in course of cancer development. Whichever the case, hypercoagulation may severely limit administration of cancer therapies, impose integrative supporting treatments and finally have an impact on p...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/849 |
id |
doaj-d9246242946349d1acbc957c790ab74d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura Pizzuti Eriseld Krasniqi Chiara Mandoj Daniele Marinelli Domenico Sergi Elisabetta Capomolla Giancarlo Paoletti Claudio Botti Ramy Kayal Francesca Romana Ferranti Isabella Sperduti Letizia Perracchio Giuseppe Sanguineti Paolo Marchetti Gennaro Ciliberto Giacomo Barchiesi Marco Mazzotta Maddalena Barba Laura Conti Patrizia Vici |
spellingShingle |
Laura Pizzuti Eriseld Krasniqi Chiara Mandoj Daniele Marinelli Domenico Sergi Elisabetta Capomolla Giancarlo Paoletti Claudio Botti Ramy Kayal Francesca Romana Ferranti Isabella Sperduti Letizia Perracchio Giuseppe Sanguineti Paolo Marchetti Gennaro Ciliberto Giacomo Barchiesi Marco Mazzotta Maddalena Barba Laura Conti Patrizia Vici Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial Cancers coagulation activation locally advanced breast cancer prognostic model pCR venous thromboembolism |
author_facet |
Laura Pizzuti Eriseld Krasniqi Chiara Mandoj Daniele Marinelli Domenico Sergi Elisabetta Capomolla Giancarlo Paoletti Claudio Botti Ramy Kayal Francesca Romana Ferranti Isabella Sperduti Letizia Perracchio Giuseppe Sanguineti Paolo Marchetti Gennaro Ciliberto Giacomo Barchiesi Marco Mazzotta Maddalena Barba Laura Conti Patrizia Vici |
author_sort |
Laura Pizzuti |
title |
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial |
title_short |
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial |
title_full |
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial |
title_fullStr |
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial |
title_full_unstemmed |
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial |
title_sort |
observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. outline of the arias trial |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-04-01 |
description |
A hypercoagulable state may either underlie or frankly accompany cancer disease at its onset or emerge in course of cancer development. Whichever the case, hypercoagulation may severely limit administration of cancer therapies, impose integrative supporting treatments and finally have an impact on prognosis. Within a flourishing research pipeline, a recent study of stage I-IIA breast cancer patients has allowed the development of a prognostic model including biomarkers of coagulation activation, which efficiently stratified prognosis of patients in the study cohort. We are now validating our risk assessment tool in an independent cohort of 108 patients with locally advanced breast cancer with indication to neo-adjuvant therapy followed by breast surgery. Within this study population, we will use our tool for risk assessment and stratification in reference to 1. pathologic complete response rate at definitive surgery, intended as our primary endpoint, and 2. rate of thromboembolic events, intended as our secondary endpoint. Patients’ screening and enrollment procedures are currently in place. The trial will be shortly enriched by experimental tasks centered on next-generation sequencing techniques for identifying additional molecular targets of treatments which may integrate current standards of therapy in high-risk patients. |
topic |
coagulation activation locally advanced breast cancer prognostic model pCR venous thromboembolism |
url |
https://www.mdpi.com/2072-6694/12/4/849 |
work_keys_str_mv |
AT laurapizzuti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT eriseldkrasniqi observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT chiaramandoj observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT danielemarinelli observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT domenicosergi observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT elisabettacapomolla observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT giancarlopaoletti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT claudiobotti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT ramykayal observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT francescaromanaferranti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT isabellasperduti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT letiziaperracchio observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT giuseppesanguineti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT paolomarchetti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT gennarociliberto observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT giacomobarchiesi observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT marcomazzotta observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT maddalenabarba observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT lauraconti observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial AT patriziavici observationalmulticenterstudyontheprognosticrelevanceofcoagulationactivationinriskassessmentandstratificationinlocallyadvancedbreastcanceroutlineoftheariastrial |
_version_ |
1724694960033234944 |
spelling |
doaj-d9246242946349d1acbc957c790ab74d2020-11-25T03:01:06ZengMDPI AGCancers2072-66942020-04-011284984910.3390/cancers12040849Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS TrialLaura Pizzuti0Eriseld Krasniqi1Chiara Mandoj2Daniele Marinelli3Domenico Sergi4Elisabetta Capomolla5Giancarlo Paoletti6Claudio Botti7Ramy Kayal8Francesca Romana Ferranti9Isabella Sperduti10Letizia Perracchio11Giuseppe Sanguineti12Paolo Marchetti13Gennaro Ciliberto14Giacomo Barchiesi15Marco Mazzotta16Maddalena Barba17Laura Conti18Patrizia Vici19Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDepartment of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyMedical Oncology Unit, Sant’Andrea Hospital, Via di Grottarossa, 1035/1039, 00189 Rome, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyRadiology Department, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyRadiology Department, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyBiostatistics Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyPathology Department, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyMedical Oncology Unit, Sant’Andrea Hospital, Via di Grottarossa, 1035/1039, 00189 Rome, ItalyScientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyMedical Oncology Unit, Ospedale dell’Angelo, Via Paccagnella 11, 30174 Mestre, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyDepartment of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, ItalyA hypercoagulable state may either underlie or frankly accompany cancer disease at its onset or emerge in course of cancer development. Whichever the case, hypercoagulation may severely limit administration of cancer therapies, impose integrative supporting treatments and finally have an impact on prognosis. Within a flourishing research pipeline, a recent study of stage I-IIA breast cancer patients has allowed the development of a prognostic model including biomarkers of coagulation activation, which efficiently stratified prognosis of patients in the study cohort. We are now validating our risk assessment tool in an independent cohort of 108 patients with locally advanced breast cancer with indication to neo-adjuvant therapy followed by breast surgery. Within this study population, we will use our tool for risk assessment and stratification in reference to 1. pathologic complete response rate at definitive surgery, intended as our primary endpoint, and 2. rate of thromboembolic events, intended as our secondary endpoint. Patients’ screening and enrollment procedures are currently in place. The trial will be shortly enriched by experimental tasks centered on next-generation sequencing techniques for identifying additional molecular targets of treatments which may integrate current standards of therapy in high-risk patients.https://www.mdpi.com/2072-6694/12/4/849coagulation activationlocally advanced breast cancerprognostic modelpCRvenous thromboembolism |